natgillin/translations-raw huggingface dataset:
The use of claim 12, wherein the at least one attenuated Salmonella or the at least one inactivated Salmonella of the Salmonella D group is Salmonella Enteritidis. 
Uporaba prema zahtjevu 12, naznačena time, da najmanje jedna atenuirana Salmonella ili najmanje jedna neaktivirana Salmonella od Salmonella skupine D je Salmonella Enteritidis.
is selected from the group consisting of -N(R3)R4 and -N(R3)C(O)-R5-N(R3)R4; and each R3 and R4 is independently selected from the group consisting of hydrogen and alkyl; 
je odabran iz skupine koja sadrži N(R3)R4 i N(R3)C(O)R5N(R3)R4; i svaki R3 i R4 je nezavisno odabran iz skupine koja sadrži vodik i alkil;
is selected from the group consisting of hydrogen, cycloalkyl and -C(O)-R5-N(R3)R4; and each R3 and R4 is independently selected from the group consisting of hydrogen and alkyl; 
je odabran iz skupine koja sadrži vodik, cikloalkil i C(O)R5N(R3)R4; i svaki R3 i R4 je nezavisno odabran iz skupine koja sadrži vodik i alkil;
The compound of Claim 17 selected from the group consisting of: 
Spoj prema zahtjevu 17 naznačen time da je odabran iz skupine koja sadrži:
A compound of formula (II): wherein: 
Spoj formule (II): [image];
is selected from the group consisting of hydrogen, halo, haloalkyl, alkoxy or alkyl; 
je odabran iz skupine koja sadrži vodik, halo, haloalkil, alkoksi ili alkil;
is selected from the group consisting of halo, pyridinyl, benzodioxolyl and phenyl optionally substituted by a substituent selected from the group consisting of cyano and alkyl; as an isolated stereoisomer or a mixture thereof, or as a pharmaceutically acceptable salt thereof, wherein alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to twelve carbon atoms. 
je odabran iz skupine koja sadrži halo, piridinil, benzodioksolil i fenil proizvoljno supstituiran sa supstituentom odabranim iz skupine koja sadrži cijano i alkil; kao izolirani stereoizomer ili njihova mješavina, ili kao njihova farmaceutski prihvatljiva sol, pri čemu se alkil odnosi na ravni ili razgranati radikal lanca ugljikovodika koji se sastoji isključivo od atoma ugljika i vodika, nije nezasićen, te ima od jedan do dvanaest atoma ugljika.
A compound of formula (V): wherein: 
Spoj formule (V): [image];
as an isolated stereoisomer or a mixture thereof, or as a pharmaceutically acceptable salt thereof, wherein alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to twelve carbon atoms. 
kao izolirani stereoizomer ili njihova mješavina, ili kao njihova farmaceutski prihvatljiva sol, pri čemu se alkil odnosi na ravni ili razgranati radikal lanca ugljikovodika koji se sastoji isključivo od atoma ugljika i vodika, nije nezasićen, te ima od jedan do dvanaest atoma ugljika.
wherein the step of preparing the (S)-enantiomer comprises treating a compound of formula (i): 
pri čemu se korak dobivanja (S)-enantiomera sastoji od obrade spoja formule (i):
with an amino donor molecule in the presence of a catalytic amount of a (S)-specific transaminase under suitable conditions to form the (S)-enantiomer. 
sa amino donorskom molekulom u prisutnosti katalitičke količine (S)-specifične transaminaze kod pogodnih uvjeta da se dobije (S)-enantiomer.
The method of Claim 21 wherein the (S)-enantiomer formed is further treated with 1,4-dibromobutane under the appropriate alkylation conditions to form the following compound: 
Postupak prema zahtjevu 21 naznačen time da je dobiveni (S)-enantiomer nadalje obrađen sa 1,4-dibromobutanom kod odgovarajućih uvjeta alkilacije da se dobije slijedeći spoj:
granulating a mixture of valsartan and excipients using water or an aqueous dispersion as granulation liquid to obtain a granulate, 
granuliranje smjese valsartana i ekscipijensa uporabom vode ili vodene disperzije kao tekućine za granuliranje kako bi se dobio granulat
compressing the compression mixture to the desired form, and 
komprimiranje smjese za komprimiranje u željeni oblik te
The process according to claim 1 wherein the compression pressure in the compression step is 25 kN or below. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je tlak kompresije u fazi kompresije 25 kN ili manji.
The process according to claim 3 wherein at least 20% of the valsartan particles have a diameter in the range of 0.02 to 50 µm. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time, da najmanje 20 % čestica valsartana ima promjer u rasponu od 0,02 do 50 pm.
The compound according to Claim 12 for use in the treatment of cancer, wherein said cancer is bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreas/gall bladder cancer, prostate cancer, thyroid cancer, osteosarcoma, rhabdomyosarcoma, melanoma, glioblastomas/astrocytomas, MFH/fibrosarcoma, or mesothelioma. 
Spoj prema zahtjevu 12 za uporabu u liječenju raka, gdje taj rak je rak mjehura, rak dojke, rak kolorektuma, rak želuca, rak glave i vrata, rak bubrega, rak jetre, rak pluća, rak jajnika, rak gušterače/žučnog mjehura, rak prostate, rak štitnjače, osteosarkom, rabdomiosarkom, melanom, glioblastomi/astrocitomi, MFH/fibrosarkom ili mezoteliom.
A suspension according to claim 1, characterized in that said smectite clay is magnesium aluminium silicate. 
Suspenzija u skladu s patentnim zahtjevom 1, naznačena time što je navedena smektitna glina magnezijev aluminijev silikat.
A suspension according to claim 1, characterized in that riluzole or said pharmaceutically salt thereof is in particle form. 
Suspenzija u skladu s patentnim zahtjevom 1, naznačena time što su riluzol ili navedena njegova farmaceutska sol u obliku čestica.
A suspension according to claim 6, characterized in that the average size of the particles of riluzole or said pharmaceutically salt thereof is lower than 200 µm. 
Suspenzija u skladu s patentnim zahtjevom 6, naznačena time što je prosječna veličina čestica riluzola ili navedene njegove farmaceutske soli ispod 200 µm.
A suspension according to claim 1, characterized in that said surfactant is selected from sodium lauryl sulphate, dioctyl sodium sulfosuccinate (sodium docusate), polyoxyethylene castor oil, polyoxyethylene fatty ethers and/or poloxamers. 
Suspenzija u skladu s patentnim zahtjevom 1, naznačena time što se navedeni surfaktant bira između natrijevog lauril-sulfata, dioktil natrijevog sulfosukcinata (natrijevog dokusata), polioksietileniranog ricinusovog ulja, polioksietileniranih masnih etera i/ili poloksamera.
A suspension according to claim 1, characterized in that said surfactant is ethoxylated fatty alcohols. 
Suspenzija u skladu s patentnim zahtjevom 1, naznačena time što navedeni surfaktant čine etoksilirani masni alkoholi.
Method according to claim 1, wherein said value is a monitoring judgment corresponding to an estimate of the probability of detecting an event in the associated cell. 
Postupak u skladu s zahtjevom 1, naznačen time, da procjena nadzora odgovara procjeni vjerojatnosti otkrivanja događaja koji nastaje u pridruženoj ćeliji.
Ibudilast or a pharmaceutically acceptable salt thereof for use in a method of alleviating the negative effects of progressive neurodegenerative disease in a human patient, wherein the patient is suffering from primary progressive or secondary progressive multiple sclerosis. 
Ibudilast, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u postupku ublažavanja negativnih posljedica progresivne neurodegenerativne bolesti kod ljudskog pacijenta, gdje pacijent boluje od primarne progresivne ili sekundarne progresivne multiple skleroze.
Ibudilast or a pharmaceutically acceptable salt thereof for use according to any one of the preceding claims, wherein the method comprises administering the ibudilast or pharmaceutically acceptable salt thereof in an amount of 30 mg to 240 mg daily. 
Ibudilast, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se postupak sastoji u primjeni ibudilasta, ili njegove farmaceutski prihvatljive soli, u količini od 30 mg do 240 mg dnevno.
Ibudilast or a pharmaceutically acceptable salt thereof for use according to any one of the preceding claims, wherein the method comprises administering ibudilast or pharmaceutically acceptable salt thereof for 1-2 years. 
Ibudilast, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se postupak sastoji u primjeni ibudilasta, ili njegove farmaceutski prihvatljive soli, u trajanju od 1-2 godine.
A host cell comprising at least one expression construct encoding a viral RNA molecule, wherein expression of the viral RNA molecule from the construct is controlled by a pol I promoter which is not endogenous to the host cell's taxonomic order. 
Postupak za dobivanje rekombinantnog virusa, koji da sadrži korak uzgoja pseće stanice domaćina koja sadrži barem jedan ekspresijski konstrukt koji kodira virusnu RNK molekulu, naznačen time da je ekspresija virusne RNK molekule iz konstrukta kontrolirana pomoću pol I promotora od primata pod uvjetima da je eksprimirana virusna RNK molekula kako bi se proizveo virus.
An aqueous preparation obtained by a process for preserving an aqueous preparation of mineral material, wherein the process comprises the steps of: 
Postupak za konzerviranje vodenog pripravka mineralnog materijala, naznačen time da postupak sadrži slijedeće korake:
providing at least one salt of a C5 - C28 fatty acid selected from the group comprising mono-alcohol primary alkanolamine salts, polyethyleneimine salts, and mixtures thereof; 
osiguravanja barem jedne soli C5 - C28 masne kiseline koja je odabrana iz skupine koja sadrži soli primarnog mono-alkohol alkanolamina, soli polietilenimina, te njihove smjese;
Process for the control of organic material in an aqueous medium, characterized in that surface-treated calcium carbonate material or an aqueous suspension comprising surface-treated calcium carbonate material according to claim 19 or 20 is added to the medium. 
Postupak za kontrolu organskog materijala u vodenom mediju, naznačen time da se u medij dodaje materijal od površinski obrađenog kalcijevog karbonata ili vodena suspenzija koja sadrži materijal površinski obrađenog kalcijevog karbonata prema zahtjevu 19 ili 20.
The process according to claim 21, characterized in that said organic material in an aqueous medium is selected from the group comprising petroleum, petroleum derivatives, stickies, pitch or mixtures thereof, said pitch being preferably non-ionic and/or anionic. 
Postupak prema zahtjevu 21, naznačen time da je navedeni organski materijal u vodenom mediju odabran iz skupine koja sadrži naftu, naftne derivate, ljepljive kontaminante, nečistoće ili njihove smjese, te su navedene nečistoće poželjno neionske i/ili anionske.
A hydroalcoholic gel pharmaceutical composition comprising: 
Farmaceutska smjesa u obliku hidroalkoholnog gela koja sadrži:
from 60 % to 80 % (w/w) of an alcohol selected from the group consisting of ethanol and isopropanol; 
od 60% do 80% (w/w) alkohola izabranog iz grupe koja obuhvaća etanol i izopropanol;
a sufficient amount of a thickening agent to give the composition a viscosity in excess of 9000 cps; and water. 
dovoljnu količinu sredstva za zgušnjavanje koje će dati smjesi viskoznost u suvišku od 9000 cps; i vodu.
15.9% (w/w) of purified water * equivalent to about 68.1% of absolute alcohol in the formulation. 
15.9% (w/w) pročišćene vode * što odgovara do oko 68.1% apsolutnog alkohola u obliku.
The composition for use according to claim 7 or the use of claim 8, wherein the subject has a pretreatment serum testosterone concentration less than 300 ng/dl. 
Smjesa za uporabu prema zahtjevu 7 ili uporabu prema zahtjevu 8, gdje je kod bolesnika prije liječenja koncentracija testosterona u serumu manja od 300 ng/dl.
The composition for use according to claim 7 or 9 or the use of claim 8 or 9, wherein a therapeutically effective dose of the composition is administered once, twice, or three times daily for at least about 7 days. 
Smjesa za uporabu prema zahtjevu 7 ili 9 ili uporabu prema zahtjevu 8 ili 9, gdje se terapijski učinkovita doza smjese primjenjuje jednom, dvaput ili triput dnevno, kroz najmanje oko 7 dana.
from 60 to 80 % (w/w) of alcohol selected from the group consisting of ethanol and isopropanol; 
od 60% do 80% (w/w) alkohola izabranog iz grupe koja obuhvaća etanol i izopropanol;
a sufficient amount of a thickening agent to give the composition a viscosity in excess of 9000 cps; and 
dovoljnu količinu sredstva za zgušnjavanje koje će dati smjesi viskoznost u suvišku od 9000 cps; i vodu.
15.9% (w/w) Purified water *equivalent to about 68.1% of absolute alcohol in the formulation. 
15.9% (w/w) pročišćene vode * što odgovara do oko 68.1% apsolutnog alkohola u obliku.
A modular canopy (14) for supporting and protecting a long, retractable sootblower (12), comprising: a front mounting structure (16) configured for attaching the canopy to an exterior surface of a furnace wall; 
Modularna nadstrešnica (14) za podupiranje i zaštitu dugog uređaja za ispuhivanje čađe na uvlačenje (12), naznačena time da sadrži: prednju montažnu konstrukciju (16) prilagođenu za pričvršćivanje nadstrešnice na vanjsku površinu stjenke ložišta;
a rear mounting structure (18); 
stražnju montažnu konstrukciju (18);
a pair of substantially parallel opposing sidewalls (21) extending from the front mounting structure to the rear mounting structure forming an open frame in which the sidewalls are substantially uncovered from above and below, removably covered from above and open from below, or covered from above and open from below; 
par u biti paralelnih nasuprotnih bočnih stijenki (21) koji se pruža od prednje montažne konstrukcije prema stražnjoj montažnoj konstrukciji koje tvore otvoreni okvir u kojem su bočne stjenke uglavnom otkrivene odozgo i odozdo, odozgo prekrivene sa mogućnošću otkrivanja i otvorene prema dolje, ili prekrivene odozgo i otvorene prema dolje;
wherein each sidewall comprises at least two substantially identical standard side panels (20); and wherein, for each sidewall, the truss is located at a junction between adjacent side panels of and connects the side panels to each other. 
pri čemu svaka bočna stjenka sadrži barem dvije uglavnom identične standardne bočne ploče (20); te pri čemu je nosač za svaku bočnu stjenku, smješten na spoju između susjednih bočnih ploča, te međusobno povezuje bočne ploče.
The modular canopy (14) of claim 1, wherein each sidewall (21) further includes at least one of the side panels (20) trimmed to a desired length. 
Modularna nadstrešnica (14) prema zahtjevu 1, naznačena time da svaka bočna stjenka (21) nadalje uključuje barem jednu bočnu ploču (20) odrezanu na željenu duljinu.
The modular canopy (14) of claim 2, wherein each sidewall (21) further includes at least two substantially identical full-length side panels (20) and an additional standard side panel trimmed to a desired length. 
Modularna nadstrešnica (14) prema zahtjevu 2, naznačena time da svaka bočna stjenka (21) nadalje uključuje barem dvije u biti identične bočne ploče (20) pune duljine, te dodatnu standardnu bočnu ploču odrezanu na željenu duljinu.
The modular canopy (14) of claim 1, wherein: the truss (22) comprises a bracket (54) and a flange (56); 
Modularna nadstrešnica (14) prema zahtjevu 1, naznačena time da: nosač (22) sadrži konzolu (54) i prirubnicu (56);
the bracket has an extended width dimension; and the flange has an extended width dimension orthogonal to the extended width dimension of the bracket. 
konzola ima proširenu dimenziju širine; i prirubnica ima proširenu dimenziju širine pravokutno na proširenu dimenziju širine konzole.
wherein each length of track comprises holes precisely located for attaching the track to the truss sections and the side panel sections; 
pri čemu svaka duljina šine sadrži precizno smještene provrte za spajanje šine sa dijelovima nosača i dijelovima bočnih ploča;
placing the standardized, surface treated side panel and truss sections into an inventory; 
postavljanje standardiziranih, površinski obrađenih dijelova bočne ploče i nosača na zalihu;
fabricating a front mounting structure (16) for the canopy; 
izrade prednje montažne konstrukcije (16) za nadstrešnicu;
fabricating a rear mounting structure (18) for the canopy; 
izrade stražnje montažne konstrukcije (18) za nadstrešnicu;
modifying a pair of the standardized side panels by trimming to give the canopy the desired length; 
izmjenu para standardiziranih bočnih ploča obrezivanjem da se dobije nadstrešnica željene duljine;
The method of claim 12, further comprising the steps of: configuring each truss (22) with a bracket (54) and a flange (56) wherein the bracket has an extended width dimension and the flange has an extended width dimension orthogonal to the extended width dimension of the bracket. 
Postupak prema zahtjevu 12, naznačen time da nadalje sadrži korake: prilagođavanja svakog nosača (22) sa konzolom (54) i prirubnicom (56) naznačen time da konzola ima proširenu dimenziju širine, te prirubnica ima proširenu dimenziju širine pravokutno na proširenu dimenziju širine konzole.
a compound of claim 1; and 
spoj prema zahtjevu 1; i
The use of claim 4, 6, or 7, wherein an effective amount of a compound of claim 1 or a composition of claim 2 is administered to the individual and further an effective amount of a tumor necrosis factor antagonist selected from the group consisting of etanercept, infliximab, and adalimumab is administered to the individual. 
Upotreba prema zahtjevu 4, 6, ili 7, naznačena time da se pojedincu administrira učinkovita količina spoja prema zahtjevu 1, ili pripravka prema zahtjevu 2 i dodatno učinkovita količina antagonista faktora tumorske nekroze izabranog iz skupine koju čini etanercept, infliximab, i adalimumab.
The compound of claim 34, 36 or 37, for use in combination with an effective amount of a tumor necrosis factor antagonist selected from the group consisting of etanercept, infliximab, and adalimumab. 
Spoj prema zahtjevu 34, 36, ili 37, naznačen time da se koristi u kombinaciji s učinkovitom količinom antagonista faktora tumorske nekroze izabranog iz skupine koju čini etanercept, infliximab, i adalimumab.
The compound of claim 34, 36 or 37, for use in combination with an effective amount of interferon-gamma (IFN-γ). 
Spoj prema zahtjevu 34, 36, ili 37, naznačen time da se koristi u kombinaciji s učinkovitom količinom interferona-gama (IFN-γ).
The compound of claim 34, 36 or 37, for use in combination with an effective amount of interferon-alpha (IFN-a). 
Spoj prema zahtjevu 34, 36, ili 37, naznačen time da se koristi u kombinaciji s učinkovitom količinom interferona-alfa (IFN-a).
A method for preparing Montelukast acid of formula 1 or the sodium salt thereof, comprising the step of coupling a thiol compound of formula 2 with a Montelukast intermediate of formula 3 in the presence of a base in a medium comprising an ionic liquid compound selected from the group consisting of the compounds of formulae 4a to 4e: wherein, R1 is hydrogen, methyl, or ethyl; 
Postupak dobivanja Montelukastove kiseline formule 1 ili njezine natrijeve soli, [image], naznačen time što se sastoji u koraku kondenziranja tiolnog spoja formule 2 [image] s Montelukastovim međuproduktom formule 3 [image], u prisutnosti baze, u mediju koji sadrži tekući ionski spoj, kojeg se bira iz skupine koju čine spojevi formula 4a do 4e:
L-O is a leaving group, wherein L is selected from the group consisting of methanesulfonyl, p-toluenesulfonyl, dimethylphosphoryl, diethylphosphoryl and diphenylphosphoryl; 
L-O je izlazna skupina, gdje se L bira iz skupine koju čine metansulfonil, p-toluensulfonil, dimetilfosforil, dietilfosforil i difenilfosforil;
The method of claim 3, wherein the ionic liquid compound is 1-ethyl-3-methylimidazolium bromide or N-butyl-N-methylpyrrolidium hexafluorophosphate. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time što ionski tekući spoj je 1-etil-3-metilimidazolijev bromid ili N-butil-N-metilpirolidijev heksafluorofosfat.
The method of claim 1, wherein the ionic liquid compound is employed in an amount ranging from 0.1 to 100 times the weight of the compound of formula 3. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se tekući ionski spoj upotrebljava u rasponu količina koje su 0,1 do 100-struka težina spoja formule 3.
The method of claim 1, wherein the base is selected from the group consisting of potassium t-butoxide, sodium t-butoxide, NaH, NaOH, and KOH. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što baza se bira iz skupine koju čine kalijev t-butoksid, natrijev t-butoksid, NaH, NaOH, te KOH.
The method of claim 6, wherein the base is potassium t-butoxide. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što baza je kalijev t-butoksid.
The system of claim 1 wherein the system is configured such that the primary drive signal or the secondary drive signal have a variable pulse duration and/or timing. 
Sustav prema zahtjevu 1, naznačen time, da je sustav namješten tako da primarni pokretački signal ili sekundarni pokretački signal ima promjenjivo vrijeme trajanja impulsa i/ili izbor trenutka - tajming.
The system of claim 1, wherein the system is configured such that the primary drive signal is variable and the secondary drive signal is variable. 
Sustav prema zahtjevu 1, naznačen time, da je sustav namješten tako da je primarni pokretački signal promjenjiv i sekundarni pokretački signal je promjenjiv.
The system of any preceding claim wherein the system is configured such that the primary drive signal and the secondary drive signal do not overlap. 
Sustav prema bilo kojem prethodnom zahtjevu, naznačen time, da je sustav namješten tako da se primarni pokretački signal i sekundarni pokretački signal ne preklapaju.
The system of any one of claims 1 to 3 wherein the system is configured such that the primary drive signal and the secondary drive signal overlap. 
Sustav prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je sustav namješten tako da se primarni pokretački signal i sekundarni pokretački signal preklapaju.
The system of claim 3 wherein the system is configured to provide the primary drive signal or the secondary drive signal with a variable pulse timing. 
Sustav prema zahtjevu 3, naznačen time, da je sustav namješten tako da omogući primarni pokretački signal ili sekundarni pokretački signal s promjenjivim tajmingom impulsa.
from 10 to 40% by weight, on the total composition weight, of at least one chlorinated organic compound selected from the group consisting of chlorinated isocyanuric acid or its salts, aromatic chloro-sulphonamide or its salts, and mixtures thereof, 
od 10 do 40 težinskih %, od ukupne težine kompozicije, najmanje jednog kloriranog organskog spoja koji je izabran iz grupe koju čine klorirana izocijanurna kiselina ili njene soli, aromatični kloro-sulfonamid ili njegove soli, i njihove smjese,
from 0 to 6% by weight of an inorganic carbonate, and veterinarily acceptable adjuvants and/or excipients, as an anti-inflammatory and/or antimicrobial agent for the prevention and treatment of foot diseases in ungulates. 
od 0 do 6 težinskih % neorganskog karbonata, i veterinarski prihvatljive adjuvante i/ili inertne punitelje, kao anti-inflamatorno i/ili antimikrobialno sredstvo za uporabu u prevenciji i liječenju bolesti stopala kod papkara i kopitara.
The use of claim 1, wherein said foot diseases are white line disease, digital dermatitis (Mortellaro Disease), interdigital dermatitis, solar ulcers, white line diathesis, laminitis, sole abscesses and interdigital phlegmon. 
Kompozicija za uporabu prema patentnom zahtjevu 1, naznačena time što su navedene bolesti stopala bolesti bijele linije, digitalni dermatitis (Mortellaro bolest), interdigitalni dermatitis, solarni ulceri, dijateza bijele linije, laminitis, apscesi tabana i interdigitalne flegmone.